Revvity (NYSE:RVTY) Rating Lowered to “Hold” at Wall Street Zen

Revvity (NYSE:RVTY) was downgraded by equities research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Sunday.

RVTY has been the subject of several other research reports. Wolfe Research started coverage on Revvity in a report on Tuesday, June 2nd. They set a “peer perform” rating for the company. Zacks Research upgraded Revvity from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 4th. JPMorgan Chase & Co. reduced their price target on shares of Revvity from $96.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, May 6th. Stifel Nicolaus decreased their price target on shares of Revvity from $110.00 to $100.00 and set a “hold” rating for the company in a research note on Wednesday, May 6th. Finally, Barclays boosted their price target on shares of Revvity from $95.00 to $105.00 and gave the company an “equal weight” rating in a research note on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, Revvity presently has a consensus rating of “Hold” and an average price target of $108.36.

Revvity Price Performance

Revvity stock opened at $116.36 on Friday. The stock’s 50 day moving average price is $109.93 and its two-hundred day moving average price is $100.00. The stock has a market capitalization of $12.98 billion, a price-to-earnings ratio of 55.41, a PEG ratio of 2.13 and a beta of 1.07. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. Revvity has a 52-week low of $81.22 and a 52-week high of $118.34.

Revvity (NYSE:RVTY) last issued its earnings results on Tuesday, August 4th. The company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.21 by $0.20. The business had revenue of $729.69 million for the quarter, compared to analyst estimates of $702.96 million. Revvity had a net margin of 8.16% and a return on equity of 8.34%. Revvity’s revenue was down 1.3% on a year-over-year basis. During the same period in the prior year, the firm earned $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts predict that Revvity will post 5.36 earnings per share for the current year.

Hedge Funds Weigh In On Revvity

Several hedge funds have recently modified their holdings of the company. Jupiter Topco LLC purchased a new position in shares of Revvity in the 2nd quarter worth approximately $961,017,000. BlackRock Inc. purchased a new stake in shares of Revvity during the second quarter valued at approximately $852,070,000. Primecap Management Co. CA bought a new stake in Revvity during the second quarter worth $94,921,000. Norges Bank bought a new stake in Revvity during the fourth quarter worth $80,382,000. Finally, Bank of America Corp DE purchased a new position in Revvity in the second quarter worth $87,116,000. Institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.